I saw it takeoff late Fri - I put in a buy at 3 prices up to .015 in the last 4 mins online trading with none of the 100K extra shares I wanted bot...so I called am trade to see if by chance they had a partial...no such luck..so Ihave to sit on my older shares LOL NO FRIDAY FILL
I put XKEM in Center Column up on my new Site Friday NIGHT
grabbagersinvestingresearch.com
the main page is not open yet Book Mark and so ...come on back
Chucka/Grabbag at Rag Bull
also I wonder if a TAX FREE MUNICPLE BOND willl come tofruition as per this part of last years Page 17 18 on !0 Q
17
--------------------------------------------------------------------------------
At the closing of the Notes, the conversion price on all previously existing and outstanding loans (principal and interest) owing from the Company to Chassman and investors was reset to $0.005 per share, and the maturity dates were extended to April 2007.
(5) Xechem Nigeria is in negotiations with UPS Capital Business Credit to obtain financing in the sum of $8,445,338 for our pharmaceutical project in Nigeria. The loan facility proposal is being processed under the Loan Guarantee Program of the Export-Import Bank of the United States ("Ex-Im Bank"). Financialbridge, Inc. has been engaged as financial consultants to facilitate the consummation of the Ex-Im Bank loan. In October 2004, Ex-Im Bank issued to Xechem Nigeria a Letter of Interest expressing its support for the proposed loan, subject to, among other things, the procurement by Xechem Nigeria of a suitable Nigerian bank guarantee in the amount of the proposed loan from an identified Nigeria-based bank. That Letter of Interest expired in October 2005. A new Letter of Interest has been obtained and is scheduled to expire in May 2006.
As of September 30, 2005, the Company has been unsuccessful in identifying an institution to provide the required guarantee for this loan. Xechem has decided to seek to syndicate the loan guarantee and is in the process of trying to identify Nigeria-based financial institutions to participate as a member of a Nigerian Bank Syndicate that will collectively guarantee the Ex-Im Bank loan. Should that occur and the loan be processed and made available to Xechem Nigeria, the funds would be used, in part, to reimburse Xechem for funds advanced to Xechem Nigeria in connection with the Nigerian project and in part to defray the ongoing costs associated with the completion of the project, all as and to the extent consistent with the Ex-Im Bank parameters. Should the loan not be consummated for any reason, Xechem will look to other sources of public and private funds to replace those that otherwise would have come from Ex-Im. Xechem cannot predict the likelihood of the Ex-Im Bank loan being consummated or of its ability to identify alternative sources of funds should the loan fail to materialize.
We have financed research and development activities principally through capital contributions and loans made by our stockholders, other investors, banks, and through funds received from the sale of State of New Jersey NOL's (net operating losses) through the New Jersey State Tax Credit Transfer program
pinksheets.com
I have no special knowledge on the subject as I reasearched other areas on my client last year July 2004 contract BUT they got a NEW JERSEY Bond this past half year:
to be put up at ( I left specific Co I rep out )(no need here )
my other site ...in part being revised...
WELCOME to our new stock research site, we have linked to some other folks on the links:
IN the Last Year I have 2 SEC Disclosures with myself as Researcher with :
I left it out no need but refer to TAX FREE MUNICIPLE bonds it was dated the date that PIEX had that NR about Casacade Investments ( Bill Gates Funding ) had out on the west cost on Ethonol./ I can not name names I don't have any affilation with Cascade INvestments or Bill Gates ( Of Course )..but found it curious that a Tax Free NEW JERSEY bond in the same subject mater ( Ethanol ) was issued the same day and thye same amount of Project BTWay. New Jersey seems very innovative this past year that is all. The XKEM HOME OFFICE is :
New Jersy is it not?
Xechem International, Inc.
--------------------------------------------------------------------------------
(Exact name of registrant as specified in its charter)
Delaware 22-3284803
-------------------------------------- ----------ate or other jurisdiction of (I.R.S. Employer Identification No.)
incorporation or organization)
100 Jersey Avenue, Bldg. B, Suite. 310, New Brunswick, NJ 08901
---------------------------------------------------Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code (732) 247-3300
-----------------------------
(Former name, former address and former fiscal year, if changed since last
report.)
Check whether the registrant (1) filed all reports required to be filed by
Section 13 of 15(d) of the Exchange Act during the past 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
Yes |X| No |_|
Number of shares outstanding of the issuer's common stock, as of November 5, 2005, was 259,688,718 shares
grabbagersinvestingresearch.com
So Email me at
grabbag@grabbager.com
or
otc-advisorchucka@grabbager.com
and I still check
Chucka@ChuckaPublicRelations.com
PS Gateway and Peaser wow yes the news is great
From: Peaser01 3/4/2006 5:13:06 PM
Read Replies (2) of 22
March 3rd, 2006
Obasanjo to launch locally produced sickle cell drug
President Olusegun Obasanjo will by June launch NIPRISAN (HEMOXIN(TM)), the locally produced drug for sickle cell disorder.
PATIENCE OGBE Abuja
The president will also use the occasion to commission Xechem International Inc. factory in the country in a move seen as a landmark investment in Nigeria. The company owns the exclusive rights to NIPRISAN
...""
RE READ:
Message 22214546
Message #5 HERE in part
"".....allowed to surrender those benefits for use by other tax-paying entities in exchange for cash payments. The goal of the Program is to offer qualifying companies financial resources to conduct research and transfer research discoveries into viable commercial products. This marks the fifth year in a row that Xechem has received cash for the sale of tax losses under the Program.
Dr. Ramesh C. Pandey, the Chairman and Chief Executive Officer of Xechem International and Xechem Inc. said "We are pleased and grateful that the State of New Jersey places such a high priority on helping advance the prospects of emerging biotechnology companies such as Xechem by allowing us to generate cash from net loss carryovers that would otherwise have little if any value to us. The monies available under the NJEDA Program have provided Xechem with a consistent source of meaningful funding year after year, and we hope and expect to continue benefiting from this worthwhile program in the years to come."
About Xechem
...." |
